New Pharmacological Strategies for the Treatment of Atrial Fibrillation
Open Access
- 9 July 2009
- journal article
- review article
- Published by Wiley in Annals of Noninvasive Electrocardiology
- Vol. 14 (3) , 290-300
Abstract
Atrial fibrillation (AF) is a growing clinical problem, increasing in prevalence as the population of the United States and countries around the world ages. Intensive research aimed at improving prevention, diagnosis, and treatment of AF is ongoing. Although the use and efficacy of catheter ablation‐based approaches in AF treatment have increased significantly in the last decade, pharmacological agents remain the first‐line therapy for rhythm management of AF. Currently available anti‐AF agents are generally only moderately effective and associated with extracardiac toxicity and/or a risk for development of life‐threatening ventricular arrhythmias. Included among current investigational strategies for improving the effectiveness and safety of anti‐AF drugs is the development of (1) Agents that produce atrial‐specific or predominant inhibition of IKur, IK‐ACh, or INa; (2) “Upstream therapies” that effect nonion channel targets that reduce atrial structural remodeling, hypertrophy, dilatation, inflammation, oxidative injury, etc; (3) Derivatives of “old” anti‐AF drugs with an improved safety pharmacological profile; and (4) Gap junction therapy aimed at improving conduction without affecting sodium channels. This review focuses on new pharmacological approaches under investigation for the treatment of AF.Keywords
This publication has 97 references indexed in Scilit:
- Can inhibition of IKur promote atrial fibrillation?Heart Rhythm, 2008
- Atrial-Selective Sodium Channel Blockers: Do They Exist?Journal of Cardiovascular Pharmacology, 2008
- Cellular bases for human atrial fibrillationHeart Rhythm, 2008
- Prevalence of early-onset atrial fibrillation in congenital long QT syndromeHeart Rhythm, 2008
- Atrial Remodeling and Atrial FibrillationCirculation: Arrhythmia and Electrophysiology, 2008
- Atrial‐Selective Sodium Channel Block as a Strategy for Suppression of Atrial FibrillationAnnals of the New York Academy of Sciences, 2008
- Ranolazine: a new antiarrhythmic agent for patients with non-ST-segment elevation acute coronary syndromes?Nature Clinical Practice Cardiovascular Medicine, 2008
- Atrium-Selective Sodium Channel Block as a Strategy for Suppression of Atrial FibrillationCirculation, 2007
- KATP channel mutation confers risk for vein of Marshall adrenergic atrial fibrillationNature Clinical Practice Cardiovascular Medicine, 2007
- Late‐Phase 3 EAD. A Unique Mechanism Contributing to Initiation of Atrial FibrillationPacing and Clinical Electrophysiology, 2006